PDF herunterladen
Clin Colon Rectal Surg 2020; 33(05): 253-257
DOI: 10.1055/s-0040-1713742
Review Article

Expanding Uses of HIPEC for Locally Advanced Colorectal Cancer: A European Perspective

Autoren

  • Delia Cortes-Guiral

    1   General Surgery Department, Principe de Asturias University Hospital, Carretera de Alcala s/n, Alcalá de Henares, Madrid, Spain

  • Olivier Glehen

    2   General Surgery Department (Surgical Oncology), Centre Hospitalier Lyon Sud (Hospices Civils de Lyon), Lyon, France
Weitere Informationen
Auch verfügbar auf
   Lizenzen und Reprints

Abstract

Locally advanced colorectal cancer is a challenge for surgeons and medical oncologist; 10 to 20% colorectal cancer debut as locally advanced disease, with tumors extending through the colon wall with perforation and/or invasion of adjacent organs or structures. Those locally advanced tumors have a worse prognostic at any stage due not only to systemic dissemination but also in a high percentage of patients, to locoregional recurrence, in fact, peritoneal carcinomatosis of colorectal origin is so predictable that we can assess the risk for each patient according to some histopathological and clinical features: small peritoneal nodules resected in the first surgery (70% probability), ovarian metastases (60%), perforated tumor onset or intraoperative tumor rupture (50%), positive cytology (40%), and pT4/mucinous pT3 up to 40%. Prophylactic or adjuvant hyperthermic intraperitoneal chemotherapy seems to be a promising strategy for patients with advanced colorectal cancer to prevent the development of peritoneal recurrence and improve prognosis of this group of patients.

Keywords

locally advanced colorectal cancer - high-risk patients - peritoneal carcinomatosis - hyperthermic intraperitoneal chemotherapy


Publikationsverlauf

Artikel online veröffentlicht:
18. September 2020

Thieme Medical Publishers
333 Seventh Avenue, New York, NY 10001, USA.